

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/73417 A1

(51) International Patent Classification⁷: C12N 5/00, 5/02, C12M 3/00

(21) International Application Number: PCT/US00/14526

(22) International Filing Date: 26 May 2000 (26.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/136,610 27 May 1999 (27.05.1999) US

(71) Applicant: THE RESEARCH FOUNDATION OF
STATE UNIVERSITY OF NEW YORK [US/US]; Suite
200, UB Commons, Amherst, NY 14228-2567 (US).

(72) Inventor: HICKS, Wesley, L., Jr.; 9714 Erie Road, An-
gola, NY 14006 (US).

(74) Agents: GOLDMAN, Michael, L. et al.; Nixon Peabody
LLP, Clinton Square, P.O. Box 31051, Rochester, NY
14603 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: *IN VITRO* CELL CULTURE DEVICE INCLUDING CARTILAGE AND METHODS OF USING THE SAME

(57) Abstract: The present invention relates to an *in vitro* cell culture device which includes a vessel comprising an inner surface, a layer of cartilage disposed on at least a portion of said inner surface, the layer of cartilage including a plurality of chondrocytes in an extracellular matrix, and a growth medium in the vessel, the layer of cartilage being bathed in the growth medium. Also disclosed is a composite cell culture prepared from the *in vitro* cell culture device, the composite cell culture includes a first layer including chondrocytes in an extracellular matrix, a second layer disposed on the first layer and including type I collagen, and a third layer disposed on the second layer and including cells at least partially covering the second layer. Further aspects of the present invention relate to methods of preparing *anin vitro* composite cell culture, methods of screening putative therapeutic agents for activity in promoting re-epithelialization of cartilaginous tissues, and methods of screening putative therapeutic agents for activity in inhibiting growth factors or proteinases.

WO 00/73417 A1

IN VITRO CELL CULTURE DEVICE INCLUDING CARTILAGE AND METHODS OF USING THE SAME

The present invention claims the priority benefit of U.S. Provisional
5 Patent Application Serial No. 60/136,610, filed May 27, 1999, which is hereby
incorporated by reference.

The present invention was funded by the National Institutes of Health,
Grant No. K08-CA01659. The U.S. Government may have certain rights in the
present invention.

FIELD OF THE INVENTION

The present invention relates to an *in vitro* cell culture including
cartilage, as well as various uses thereof, including screening for compounds which
15 can modify cell/cell or cartilage/cell interactions.

BACKGROUND OF THE INVENTION

Restoration of epithelial tissue after tissue injury is a complex process,
20 which includes several critical events, including deposition of extracellular matrix
("ECM"), tissue remodeling, and angiogenesis. These events are coordinated with
epithelial cell migration and proliferation to restore the epithelial and/or mucosal
barrier (i.e., in epithelial tissues such as tracheal epithelium which secrete mucous).
The coordination of these events is believed to involve the interaction between
25 different classes of cells as well as between cells and their extracellular matrix.

Failure of reepithelialization after injury has been observed in the
cornea (Fini et al., "Expression of Collagenolytic/Gelatinolytic Metalloproteinases by
Normal Cornea," Invest. Ophthalmol. Vis. Sci. 31:1779-1788 (1990)) and in chronic
wounds (Stacey et al., "Tissue and Urokinase Plasminogen Activators in the Environs
30 of Venous and Ischemic Leg Ulcers," Br. J. Surg. 80:595-599 (1993); Wysocki et al.,
"Wound Fluid from Chronic Leg Ulcers Contains Elevated Levels of
Metalloproteinases MMP-2 and MMP-9," J. Invest. Dermatol. 101:64-68 (1993);
Madlener et al., "Matrix Metalloproteinases (MMPs) and their Physiological

Inhibitors (THAPs) are Differentially Expressed During Excisional Skin Wound Repair," Exp. Cell Res. 242:201-210 (1998); Di Colandrea et al., "Epidermal Expression of Collagenase Delays Wound-healing in Transgenic Mice," J. Invest. Dermatol. 11:1029-1033 (1998)). Proteinases that destroy the basement membrane over which epithelial cells migrate have been implicated as mediators in impaired capacity to reepithelialize.

Tissue remodeling during wound healing is critical for repair as cellular migration over an appropriate ECM requires controlled and tightly regulated proteolytic degradation of the ECM, with consequent activation or release of matrix-bound growth factors (Clark, "Basics of Cutaneous Wound Repair," J. Dermatol. Surg. Oncol. 19:693-706 (1993); Salo et al., "Expression of Matrix Metalloproteinase-2 and -9 During Early Human Wound Healing," Lab. Invest. 70:176-182 (1994); Vaalamo et al., "Patterns of Matrix Metalloproteinase and TIMP-1 Expression in Chronic and Normally Healing Human Cutaneous Wounds," Br. J. Dermatol. 135:52-59 (1996); Moses et al., "Temporal Study of the Activity of Matrix Metalloproteinases and Their Endogenous Inhibitors During Wound Healing," J. Cell. Biochem. 60:379-386 (1996); Martin "Wound Healing - Aiming for Perfect Skin Regeneration," Science 276:75-81 (1997); Arumagam et al., "Temporal Activity of Plasminogen Activators and Matrix Metalloproteinases During Cutaneous Wound Repair," Surgery 125:5887-593 (1999)).

As with the above-described tissues, reepithelialization of injured tracheal tissues is often incomplete. The ability of respiratory epithelial cells ("RECs") to migrate and proliferate and restore denuded areas of the large conducting airway after injury is poor. Post-trauma restoration is pathologically manifested by the exuberant proliferation of granulation tissue and replacement of the normal respiratory epithelium with fibroblasts (Clark, "The Commonality of Cutaneous Wound Repair and Lung Injury," Chest. 99(Suppl.):57S-60S (1991); Grillo, "Tracheal Replacement," Ann. Thorac. Surg. 49:864-865 (1990)). This often leads to scar formation, airway stenosis, and eventual physiologic compromise of the host respiratory tract.

There is currently no effective way to study events of reepithelialization after injury, particularly with respect to the intraluminal events

surrounding tracheal repair. Present approaches to tracheal repair include resection and reanastomosing the injured airway, replacement of the damaged portion by synthetic material, and use of autologous tissue for reconstruction of the tracheal defect (Letang et al., "Experimental Reconstruction of the Canine Trachea with a Free Revascularized Small Bowel Graft," Ann. Thorac. Surg. 49:955-958 (1990); Mulliken et al., Abstract, "The Limits of Tracheal Resection with Primary Anastomosis: Further Anatomical Studies in Man," J. Thorac. Cardiovasc. Surg. 55:418 (1968); Neville et al., "Prosthetic Reconstruction of the Trachea and Carina," J. Thorac. Cardiovasc. Surg. 72:525-536 (1976)). Recently, tissue engineering approaches have been taken, including forming an *in vivo* tracheal cartilaginous scaffolding by injecting dissociated chondrocytes into a preformed synthetic construct (Hirano et al., "Hydroxylapatite for Laryngotracheal Framework Construction. Ann. Otol. Rhinol. Laryngol. 98:713-717 (1989); Okumura et al., "Experimental Study of a New Tracheal Prosthesis Made from Collagen Grafted Mesh," Trans. Am. Soc. Artif. Organs. 37:M317-M319 (1991); Langer et al., "Tissue Engineering," Science 260:920-926 (1993)). Such devices were of limited success owing to lack of reepithelialization. In the case of synthetic replacement, migration of the prosthesis can occur and may result in chronic ulceration, and even fatal hemorrhage (Grillo, "Tracheal Replacement," Ann. Thorac. Surg. 49:864-865 (1990)).

A frequent problem seen in tracheal repair with synthetic or autologous materials is the failure of luminal surface reepithelialization. Failure of reepithelialization to reestablish luminal integrity is an important reason why no acceptable surgical procedure exists for the repair of extended segments of trachea compromised by inhalation injury, congenital anomalies, or neoplastic disease.

Why the rate of reepithelialization in the large conducting airway is different from that seen within other epithelial-lined or -covered surfaces is unclear. The phenomenon of "slowed" reepithelialization is seen after both ablative surgical reconstruction and denudation injury, where the epithelium and basement membrane are removed with an intact cartilaginous superstructure (e.g., inhalation injury).

One of the difficulties in understanding the relationship between epithelium and its underlying substructure (cartilage and submucosa) is the inaccessibility of the tissue for direct observation. It would be desirable, therefore, to

provide an *in vitro* cell culture which includes a developed substructure or cartilaginous layer which can be used to study epithelial cell development.

The present invention is directed to overcoming these and other deficiencies in the art.

5

SUMMARY OF THE INVENTION

One aspect of the present invention relates to an *in vitro* cell culture device which includes a vessel including an inner surface, a layer of cartilage disposed on at least a portion of the inner surface, the layer of cartilage including a plurality of chondrocytes in an extracellular matrix, and a growth medium in the vessel, the layer of cartilage being bathed in the growth medium.

A further aspect of the present invention relates to a composite cell culture which includes a first layer including chondrocytes in an extracellular matrix, a second layer disposed on the first layer and including type I collagen, and a third layer disposed on the second layer and including cells at least partially covering the second layer.

Another aspect relates to a method for preparing an *in vitro* composite cell culture. This method is carried out by providing an *in vitro* cartilage layer that includes chondrocytes in an extracellular matrix, disposing a type I collagen layer on the cartilage layer, and contacting the type I collagen layer with epithelial cells under conditions effective for the epithelial cells to multiply and at least partially cover the layer of type I collagen.

Still another aspect of the present invention relates to a method of screening putative therapeutic agents for activity in promoting re-epithelialization of cartilaginous tissues. According to one approach, the method is carried out by introducing a putative therapeutic agent into a composite cell culture of the present invention and then assessing epithelial cell growth on the composite cell culture, wherein increased surface area coverage of a plurality of distinct plaques of epithelial cells indicates that the putative therapeutic agent has activity in promoting re-epithelialization of cartilaginous tissues. Alternatively, this method is carried out by providing an *in vitro* cell culture device of the present invention, introducing a layer

of type I collagen onto the layer of cartilage, introducing epithelial cells onto the layer of type I collagen to form a composite cell culture, introducing a putative therapeutic agent into the composite cell culture, and assessing epithelial cell growth on the composite cell culture, wherein growth and migration of epithelial cells beyond
5 distinct plaques thereof indicates that the putative therapeutic agent has activity in promoting re-epithelialization of cartilaginous tissues.

Yet another aspect of the present invention related to a method of screening putative therapeutic agents for activity in inhibiting a growth factor or proteinase which prevents re-epithelialization of cartilaginous tissues. According to
10 one approach, this method is carried out by introducing a putative therapeutic agent into a composite cell culture of the present invention and assessing epithelial cell growth on the composite cell culture, wherein increased surface area coverage of a plurality of distinct plaques of epithelial cells indicates that the putative therapeutic agent has activity in inhibiting a growth factor or proteinase which prevents re-
15 epithelialization. Alternatively, this method is carried out by providing an *in vitro* cell culture device of the present invention, introducing a layer of type I collagen onto the layer of cartilage, introducing epithelial cells onto the layer of type I collagen to form a composite cell culture, introducing a putative therapeutic agent into the composite cell culture, and assessing epithelial cell growth on the composite cell culture,
20 wherein growth and migration of epithelial cells beyond distinct plaques thereof indicates that the putative therapeutic agent has activity in inhibiting a growth factor or proteinase which prevents re-epithelialization.

The *in vitro* cell culture device of the present invention enables the growth of cells on an *in vitro* cartilage substructure, which enables the study of cell-
25 cell interactions between chondrocytes and other cell types introduced onto the cell culture device, as well as cell-matrix interactions between cartilage and other cell types introduced onto the cell culture device. When collagen inserts are placed onto the cell culture device and isolated cells or tissues are introduced onto the collagen inserts, the resulting composite cell culture can similarly be used. In addition, the *in vitro* cell culture device and composite cell culture can be used to screen various
30 therapeutic agents for their ability to modify such cell-cell or cell-matrix interactions, both on a cellular level as well as on a molecular level. The *in vitro* cell culture

device and composite cell culture will facilitate the development of systems in which graft tissues can be raised *in vitro* for subsequent grafting onto a patient, preferably using the patient's own cells so as to avoid any undesirable immune reactions.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a partially exploded view of an *in vitro* cell culture device of the present invention which has been used to prepare a composite cell culture of the present invention.

10

Figures 2A-C are enlarged images showing bovine chondrocytes in culture for 28 days after isolation. Figure 2A shows hematoxylin-eosin staining at 165x; Figure 2B shows electron microscopy at 300x; and Figure 2C shows type II collagen staining at 83x.

15

Figures 3A-D are enlarged images by scanning electron micrograph of day 14 control and composite cell cultures. Figures 3A and 3B illustrate the difference between confluent epithelium on the control cell culture (3A, magnification 32x) and distinct patches of respiratory epithelium on the composite cell culture (3B, magnification 100x). Figures 3C (magnification 32x) and 3D (magnification 100x) illustrate respiratory epithelium on composite cell cultures, with arrows indicating nonconfluent epithelium.

20

25

Figure 4 is an image of a gel electrophoresis of RNA transcripts isolated from day 14 respiratory epithelial cells from control and composite cell cultures. M represents an RNA ladder; lane 1, β -actin from control culture; lane 2, β -actin from composite culture; lane 3, transforming growth factor- α ("TGF- α ") from control culture; lane 4, TGF- α from composite culture; lane 5, transforming growth factor- β ("TGF- β ") from control culture; lane 6, TGF- β from composite culture.

30

Figures 5A-B are images illustrating the results of gelatin zymography for matrix metalloproteinase ("MMP") activity performed on media conditioned by respiratory epithelial cells and chondrocytes. Pre-stained molecular weight markers and purified MMP-2 and -9 standards were included. Serum-free media ("SFM") and REC-conditioned media were mixed with sample buffer and run undiluted. Chondrocyte-conditioned media ("CCM") was diluted 5-fold in sample buffer.

Figure 5A represents a Coomassie blue-stained gelatin zymogram run in the absence of EDTA. Clear areas represent zones of substrate lysis. Figure 5B represents a zymogram incubated with the divalent cation chelator EDTA. MW, molecular weight marker proteins with individual bands indicated; lane 1, MMP standards (5 ng/n-d); lane 2, MMP standards (1 ng/ml); lane 3, SFM; lane 4, REC-conditioned medium; lane 5, day 3 serum-containing CCM; lane 6, day 3 serum-free CCM. Upper arrow indicates MMP-9 (92 kDa gelatinase); lower arrow indicates MMP-2 (72 kDa gelatinase).

Figure 6 is a graph illustrating the effect of CCM in reducing proliferation of REC. Viability of the control and treated cultures was equivalent ($97.7 \pm 1.0\%$ for control; $94.1 \pm 2.90\%$ for CCM). Values represent average cell number \pm SEM from triplicate cultures in a representative experiment; * indicates a significant difference ($P < 0.01$) between control and treated cultures.

Figure 7A-B are images illustrating the results of gel zymography for MMP activity performed on chondrocyte cultured medium with either an MMP inhibitor or its negative control. Figure 7A shows medium collected on day 3 of culture and Figure 7B shows medium collected on day 7. Lane 2, MMP-2/MMP-9 standards (10 ng/ml). Upper arrow indicates 92 kDa gelatinase (MMP-9) and lower arrow indicates 72 kDa gelatinase (MMP-2). Media were pre-incubated with *p*-aminophenylmercuric acetate to activate latent enzyme activity prior to analysis. Lane 3, SFM; lane 4, day 3 REC conditioned medium; lane 5, control SFM; lane 6, control + negative drug; lane 7, CCM; lane 8, CCM + GM6001; lane 9, CCM + negative drug.

Figure 8 is a graph illustrating the influence of MMP inhibitor on REC proliferation in the presence of CCM with either 10 nM GM6001, the MMP inhibitor, or control drug; similar results were obtained using 50 nM. Values represent mean cell number \pm SEM from triplicate dishes in a representative experiment. Viability ranged from 91-89% and were not significantly different among the treatment groups; * indicates a significant difference between control and treated groups with $p < 0.01$ and ** indicates a significant difference with $p < 0.001$.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention relates to an *in vitro* cell culture device which can be used to grow cells and study cell-cartilage or cell-cell interactions, to measure the efficacy of potential therapeutic agents on chondrocytes or other cell types, and to grow tissues with developed substructure for subsequent implantation.

The *in vitro* cell culture device includes a vessel having an inner surface, a layer of cartilage disposed on at least a portion of the inner surface, where the layer of cartilage includes a plurality of chondrocytes in an extracellular matrix, and an amount of growth medium in the vessel sufficient to bathe the layer of cartilage.

The vessel can be any suitable walled structure which enables development of an *in vitro* cell culture device or three-dimensional composite cell culture of the present invention. The vessel is preferably formed of glass or a high-grade thermoplastic material which is suitable for such uses.

According to one embodiment, illustrated in Figure 1, the vessel of the *in vitro* cell culture device 10 is in the form of a petri dish having upper 12 and lower 14 members. The lower member 14 has an inner surface 16 defined by bottom 18 and integral sidewall 20. The layer of cartilage 30 is present adjacent to the bottom 18. When used to grow a composite cell culture of the present invention, as shown in Figure 1, a layer of collagen (e.g., type I collagen) 32 is disposed on the layer of cartilage 30, and a partial layer of cells 34 is deposited on the layer of collagen 32. As shown, the partial layer of cells 34 develops to form discrete patches or plaques of cells rather than a confluent layer of such cells. By introducing a therapeutic agent capable of enabling cell proliferation and migration, the partial layer of cells 34 is then allowed to grow to confluence.

The chondrocytes used in the *in vitro* cell culture device of the present invention can be any suitable type of chondrocyte. Chondrocytes are cells found in various types of cartilage, e.g., articular (or hyaline) cartilage, elastic cartilage, and fibrocartilage. Specifically, chondrocytes are mesenchymal cells that have a characteristic phenotype based primarily on the type of extracellular matrix they

produce. Precursor cells produce type I collagen, but when they become committed to the chondrocyte lineage, they synthesize type II collagen, which is a substantial portion of the extracellular matrix. In addition, committed chondrocytes produce proteoglycan aggregate, called aggrecan, which has glycosaminoglycans that are highly sulfated.

According to one embodiment of the present invention, the chondrocytes employed in an *in vitro* cell culture device are upper airway cartilage chondrocytes.

Suitable chondrocytes can be isolated from any suitable mammalian source organism, including, without limitation, human, orangutan, monkey, chimpanzee, dog, cat, rat, mouse, horse, cow, pig, etc.

Chondrocyte cells used for preparation of the *in vitro* cell culture device of the present invention can be isolated by any suitable method. Various starting materials and methods for chondrocyte isolation are known (see generally, Freshney, Culture of Animal Cells: A Manual of Basic Techniques, 2d ed., A.R. Liss Inc., New York, pp 137-168 (1987); Klagsburn, "Large Scale Preparation of Chondrocytes," Methods Enzymol. 58:560-564 (1979), which are hereby incorporated by reference) and are easily reproduced by those of skill in the art.

If the starting material is a tissue in which chondrocytes are essentially the only cell type present, e.g., articular cartilage, the cells can be obtained directly by conventional collagenase digestion and tissue culture methods. Alternatively, the cells can be isolated from other cell types present in the starting material. One known method for chondrocyte isolation includes differential adhesion to plastic tissue culture vessels. In a second method, antibodies that bind to chondrocyte cell surface markers can be coated on tissue culture plates and then used selectively to bind chondrocytes from a heterogeneous cell population. In a third method, fluorescence activated cell sorting (FACS) using chondrocyte-specific antibodies is used to isolate chondrocytes. In a fourth method, chondrocytes are isolated on the basis of their buoyant density, by centrifugation through a density gradient such as Ficoll.

It may be desirable in certain circumstance to utilize chondrocyte stem cells rather than differentiated chondrocytes. Examples of tissues from which stem cells for differentiation, or differentiated cells suitable for transdifferentiation, can be

isolated include placenta, umbilical cord, bone marrow, skin, muscle, periosteum, or perichondrium. Cells can be isolated from these tissues by explant culture and/or enzymatic digestion of surrounding matrix using conventional methods.

Once the chondrocytes have been isolated, they are preferably plated onto collagen inserts at a suitable cell density (i.e., about 20 to about 40 x 10⁶ cells per well) in a suitable growth medium. A number of suitable chondrocyte growth media are known in the art and modifications of known growth media can readily be made to optimize growth of such chondrocytes and their formation of an extracellular matrix. One suitable growth medium includes Dulbecco's modified Eagle's medium ("DMEM") containing 10% fetal bovine serum (FBS), 1% antibiotics and 50 µg/ml ascorbic acid (Gibco, Grand Island, NY). Other known culture media include, without limitation, RPMI 1640, Fisher's, Iscove's or McCoy's, all of which are commercially available. Other additives may also be included in the chondrocyte growth medium, such as platelet-derived growth factor ("PDGF"), which has been shown to increase cartilage cell number without promoting further differentiation along the endochondral differentiation pathway (see U.S. Patent No. 6,001,352 to Boyan et al., which is hereby incorporated by reference).

The collagen inserts preferably contain substantially pure type I collagen, i.e., at least 80% type I collagen, preferably at least 85% type I collagen, and more preferably, at least 90% type I collagen. The chondrocytes are maintained for about 21 to about 30 days or until the extracellular matrix is sufficiently developed. Suitable development of the extracellular matrix, denoting cartilage formation, is demonstrated by the following observations: opacity of culture, thickness of culture (i.e., between about 2-4 mm), and the firmness. This is achieved when the culture is brought to air interface.

Having established the development of the layer of chondrocytes in extracellular matrix within the vessel, the *in vitro* cell culture device can then be used to (i) study the relationship or interaction between chondrocytes and/or the extracellular matrix ("ECM") with other cells or tissues that can be introduced into the *in vitro* cell culture device; (ii) identify putative therapeutic agents which are capable of modifying cell-cell or cell-ECM interactions; or (iii) grow developed tissues along with substructure for subsequent implantation.

After development of the extracellular matrix, a second layer which includes collagen, preferably type I collagen, is applied over the layer of chondrocytes in the extracellular matrix (i.e., cartilage). The type I collagen preferably forms a substantial portion of the second layer. The type I collagen can readily be isolated and purified from a number of sources or it is otherwise commercially available, for example, from Vitrogen, Collagen Biomaterials (Palo Alto, CA). The type I collagen is preferably at least about 80% pure, more preferably at least about 85% pure, most preferably about 90% pure. It can be applied over the cartilage layer until a thickness of about 0.5-2 mm is achieved. Obviously, the volume of type I collagen which is needed to achieve such thickness will vary with the size of the vessel in which the culture resides.

On top of the second layer containing collagen is applied a growth medium including a particular type of cell(s), whose growth in the *in vitro* cell culture device is desired. Once introduced onto the second layer, a third layer is formed which includes the cells at least partially covering the second layer.

Suitable cell types which can be used to develop a three-dimensional, composite cell culture include epithelial cells, fibroblasts, endothelial cells, epidermal cells, muscle cells, or combinations thereof. The cells can be isolated from any tissue source of a suitable mammalian organism. The mammalian organism can be the same or different from the organism from which the chondrocytes were obtained. The cells can be added to the layer of collagen at rate of about $1.0 - 10.0 \times 10^5$ cells per cm^2 , preferably about $1.0 - 5.0 \times 10^5$ cells per cm^2 , more preferably about $1.5 - 3.5 \times 10^5$ cells per cm^2 . Suitable growth media include those described above, or otherwise known in the art for growth of particular cell types.

Once the cells have been introduced onto the collagen layer in the *in vitro* cell culture device, the cells should be allowed to grow until the cell layer has grown to confluence or until the growth of such cells otherwise has sufficiently mimicked *in vivo* growth of such cells. Once the growth of cells has been established, whether to confluence or not, the *in vitro* cell culture device contains a composite cell culture of the present invention. The composite cell culture represents a three-dimensional tissue model that is particularly well adapted for studying cell-cell or cell-substructure interactions.

--

A further aspect of the present invention relates to a method of preparing an *in vitro* composite cell culture. This method is carried by providing an *in vitro* cartilage layer including chondrocytes in an extracellular matrix, disposing a collagen (e.g., type I collagen) layer on the cartilage layer, and then contacting the
5 collage layer with cells under conditions effective for the cells to multiply and at least partially cover the layer of collagen.

As described above, the method can also include providing a collagen (e.g., type I collagen) substrate on which the *in vitro* cartilage layer can be raised. Providing the *in vitro* cartilage layer can be carried out by first providing a
10 chondrocyte single cell suspension and then culturing the chondrocytes under conditions effective to form an extracellular matrix, thereby forming cartilage *in vitro*. The culturing of chondrocytes, as noted above, is carried out by introducing the chondrocyte single cell suspension onto the collagen substrate, preferably at a cell density of about $1-10 \times 10^6$ cells/cm².

15 The chondrocyte single cell suspension can be obtained according to any of the above-mentioned approaches for isolating chondrocytes. A preferred approach is carried out by providing articular cartilage which includes chondrocytes embedded in an extracellular matrix, and then treating the articular cartilage with collagenase II under conditions effective to digest the extracellular matrix and
20 produce a chondrocyte single cell suspension.

According to one embodiment of the present invention, which is illustrated in Figure 1, the growth of RECs in an *in vitro* cell culture device of the present invention mimics the reepithelialization of injured tracheal tissues. Chondrocytes are isolated from bovine articular cartilage and cells introduced onto
25 the collagen layer are basal epithelial cells, secretory epithelial cells, or a combination thereof, isolated from upper respiratory tract epithelial tissues (i.e., bronchus, nasal polyps, or turbinates). The upper respiratory tract epithelium can be dissociated using any suitable method, for example, as described in Hicks et al., Abstract, "Rapid Isolation of Upper Respiratory Cells," Mol. Biol. Cell. 5(Suppl):118a (1994), which is
30 hereby incorporated by reference. The isolated epithelial cells are introduced onto the collagen layer in a suitable growth medium and at a rate indicated above. The ability of RECs to migrate and proliferate to restore denuded areas of the large conducting

airway after injury is poor, often resulting in incomplete reepithelialization. This embodiment of the *in vitro* cell culture device mimics the *in vivo* pattern of reepithelialization, yielding discrete patches of the RECs rather than a confluent layer of RECs.

5 Without being bound by any particular theory, it is believed that communication between epithelial cells and underlying substructure (i.e., chondrocytes and/or extracellular matrix) is responsible for modulation of epithelial cell growth and differentiation through the release of growth factors and other proteins. Secreted agents which are believed to modify REC growth include matrix
10 metalloproteinases ("MMPs") and transforming growth factors ("TGF"):

 Transforming growth factor- α ("TGF- α ") is a member of the epidermal growth factor family and plays an important role in wound healing (Schultz et al., "Epithelial Wound Healing Enhanced by Transforming Growth Factor- α and Vaccinia Growth Factor," Science 235:350-352 (1987); Polk et al., "Increased
15 Production of Transforming Growth Factor- α Following Acute Gastric Injury," Gastroenterology 102:1467-1474 (1992); and Madtes et al., "Expression of Transforming Growth Factor- α and Epidermal Growth Factor Receptor is Increased Following Bleomycin-Induced Lung Injury in Rats," Am. J. Respir. Cell Mol. Biol. 11: 540-551 (1994), which are hereby incorporated by reference). Transforming
20 growth factor β_1 ("TGF- β ") is a multifunctional polypeptide with differing cell-specific effects, including stimulation or inhibition of proliferation, and regulation of extracellular matrix production and remodeling (Massague et al., "The Transforming Growth Factors Family," Ann. Rev. Cell. Biol. 6:597-641 (1990); Raghow, Role of Transforming Growth Factors in Repair and Fibrosis," Chest 99(Suppl.):61S-65S
25 (1991); and Santala et al., "Regulation of Integrin-Type Cell Adhesion Receptors by Cytokines," J. Biol. Chem. 266:23505-23509 (1991), which are hereby incorporated by reference).

 MMPs constitute a family of zinc-containing proteinases acting at neutral pH, that together are capable of degrading all components of the extracellular
30 matrix. Substrates include collagen, gelatin, elastin, fibronectin, laminin, and proteoglycans, as well as nonmatrix substrates such as insulin-like growth factor-binding protein-3, tumor necrosis factor- α , fibroblast growth factor receptor 1, and

angiogenic factors (Sehgal et al., "Novel Regulation of Type IV Collagenase (Matrix Metalloproteinase-9 and -2) Activities by Transforming Growth Factor- β 1 In Human Prostate Cancer Cell Lines," Mol. Biol. Cell. 10:407-416 (1999), which is hereby incorporated by reference). They are secreted in latent form as propeptides requiring activation for proteolytic activity, and are inhibited by endogenous tissue inhibitors of metalloproteinases (Nagase et al., "Involvement of Tissue Inhibitors of Metalloproteinases (TEMps) During Matrix Metalloproteinase Activation," Adv. Exp. Med. Biol. 389:23-31 (1996); Parsons et al., "Matrix Metalloproteinases," Br. J. Surg. 84:160-166 (1997); Shapiro, "Matrix Metalloproteinase Degradation of Extracellular Matrix: Biological Consequences," Curr. Opin. Cell. Biol. 10:602-608 (1999); Toi et al., "Metalloproteinases and Tissue Inhibitors of Metalloproteinases," Breast Cancer Res. Treat. 52:113-124 (1998), which are hereby incorporated by reference). Marker protein synthesis is transcriptionally enhanced by several growth factors including epidermal growth factor, basic fibroblast growth factor, platelet-derived growth factor, and nerve growth factor, and by inflammatory cytokines such as tumor necrosis factor- α and interleukin-1. Inhibitory agents include transforming growth factor-P, retinoic acid, gamma interferon, glucocorticoids, progesterone, and estrogen (Nagase et al., "Involvement of Tissue Inhibitors of Metalloproteinases (TEMps) During Matrix Metalloproteinase Activation," Adv. Exp. Med. Biol. 389:23-31 (1996); Sehgal et al., "Novel Regulation of Type IV Collagenase (Matrix Metalloproteinase-9 and -2) Activities by Transforming Growth Factor- β 1 in Human Prostate Cancer Cell Lines," Mol. Biol. Cell. 10:407-416 (1999), which are hereby incorporated by reference). Inappropriate or excessive production of MMPs may contribute to tissue destruction in arthritis, multiple sclerosis, periodontal disease, cardiovascular disease, tumor progression, and chronic pulmonary obstructive disease (Shapiro, "Matrix Metalloproteinase Degradation of Extracellular Matrix: Biological Consequences," Curr. Opin. Cell. Biol. 10:602-608 (1999), which is hereby incorporated by reference).

In particular, MMP-2 and -9 (type IV collagenases/gelatinases proenzymes are produced by chondrocytes and play a major role in cartilage remodeling and loss of extracellular matrix in osteoarthritis (Lefebvre et al., "Production of Gelatin-degrading Matrix Metalloproteinases ('Type IV

Collagenases') and Inhibitors by Articular Chondrocytes During their Dedifferentiation by Serial Subcultures and Under Stimulation by Interleukin-1 and Tumor Necrosis Factor α ," Biochem. Biophys. Acta. 1094:8-18 (1991), which is hereby incorporated by reference).

5 Since one embodiment of the *in vitro* composite cell culture of the present invention mimics the *in vivo* cartilage/epithelial cell interactions following tracheal injury, this particular composite cell culture can be used to screen for putative therapeutic agents which can promote proper reepithelialization of cartilaginous tissues. Generally, this aspect of the present invention is carried out by introducing a
10 putative therapeutic agent into a composite cell culture or *in vitro* cell culture device of the present invention and assessing cell (e.g., epithelial cell) growth on the composite cell culture.

 This aspect of the present invention can be used to screen putative therapeutic agent(s) for their ability to inhibit normal *in vivo* collagen/epithelial cell
15 interaction or, more specifically, the effect of matrix metalloproteinases or growth factors on such epithelial cells. Putative therapeutic agent(s) can be introduced, either alone or in combination, onto the *in vitro* cell culture device either before the addition of the epithelial cells, at the same time the epithelial cells are introduced (i.e., in the same medium), or thereafter. The putative therapeutic agent(s) can then be screened
20 for their ability to disrupt the undesirable inhibition of epithelial cell growth and proliferation. Statistically significant cell growth or proliferation of epithelial cells while in the presence of a putative therapeutic agent will indicate an ability of the therapeutic agent to enable re-epithelialization of cartilage substructure following tracheal injury. Effectiveness of the putative therapeutic agent can be detected, for
25 example, by measuring increased surface area coverage of the plurality of distinct plaques. In some cases, the epithelial cells can even grow to confluence.

 According to one embodiment, the screening of putative therapeutic agents for activity in promoting re-epithelialization of cartilaginous tissues is carried out by introducing a putative therapeutic agent into a composite cell culture of the
30 present invention and then assessing epithelial cell growth on the composite cell culture, wherein increased surface area coverage of the plurality of distinct plaques

indicates that the putative therapeutic agent has activity in promoting re-epithelialization of cartilaginous tissues.

According to another embodiment, the screening of putative therapeutic agents for activity in promoting re-epithelialization of cartilaginous tissues is carried out by providing an *in vitro* cell culture device of the present invention, introducing a layer of type I collagen onto the layer of cartilage, introducing epithelial cells onto the layer of type I collagen, thereby forming a composite cell culture, introducing a putative therapeutic agent into the composite cell culture, and then assessing epithelial cell growth on the composite cell culture, wherein growth and migration of epithelial cells beyond distinct plaques thereof indicates that the putative therapeutic agent has activity in promoting re-epithelialization of cartilaginous tissues.

According to a further embodiment, the screening of putative therapeutic agents for activity in inhibiting a growth factor or proteinase which prevents re-epithelialization of cartilaginous tissues is carried out by introducing a putative therapeutic agent into a composite cell culture of the present invention and then assessing epithelial cell growth on the composite cell culture, wherein increased surface area coverage of the plurality of distinct plaques indicates that the putative therapeutic agent has activity in inhibiting a growth factor or proteinase which prevents re-epithelialization.

According to a yet another embodiment, the screening of putative therapeutic agents for activity in inhibiting a growth factor or proteinase which prevents re-epithelialization of cartilaginous tissues is carried out by providing an *in vitro* cell culture device of the present invention, introducing a layer of type I collagen onto the layer of cartilage, introducing epithelial cells onto the layer of type I collagen, thereby forming a composite cell culture, introducing a putative therapeutic agent into the composite cell culture, and then assessing epithelial cell growth on the composite cell culture, wherein growth and migration of epithelial cells beyond distinct plaques thereof indicates that the putative therapeutic agent has activity in inhibiting a growth factor or proteinase which prevents re-epithelialization.

Following identification of suitable therapeutic agents which will allow for *in vitro* growth of confluent cell layers in a composite cell culture of the present invention, it is possible to prepare *in vitro* graftable tissue specimens that contain

layers of cells over a substructural layer of cartilage. Such graftable tissue specimens can then be introduced into a patient using procedures known in the art.

EXAMPLES

The following examples are provided to illustrate embodiments of the present invention, but they are by no means intended to limit its scope.

Example 1 - Isolation and Culture of Chondrocytes

Chondrocytes were harvested from bovine articular cartilage under clean conditions, minced finely, and digested for 12 to 16 hours at 37°C in phosphate buffered saline containing antibiotics, collagenase II (Worthington, Freehold, NJ), and DNase I (Sigma-Aldrich Corporation, St Louis, Mo) as described by Klagsburn, "Large Scale Preparation of Chondrocytes," Methods Enzymol. 58:560-564 (1979), which is hereby incorporated by reference. Cell viability was determined by trypan blue staining, and cell type was confirmed by staining with hematoxylineosin and antibody to extracellular type II collagen. Chondrocytes were plated on collagen inserts (Co Eagle medium star Transwell; VWR, Rochester, NY) at 20 to 40 X 10⁶ cells per well in Dulbecco DMEM/F12 (Gibco, Grand Island, NY) modified with antibiotics, 10% fetal calf serum, and 50-µg/mL ascorbic acid.

As shown in Figures 2A-B, bovine chondrocytes established in primary culture were morphologically similar to *in vivo* bovine cartilage. Cartilage cultured for less than 2 months did not always form lacunae, but always produced an abundant extracellular matrix of type II collagen (Figure 2C).

Example 2 - Isolation of Upper Respiratory Epithelial Cells

Human tissue specimens were obtained through Manhattan Eye, Ear, Nose and Throat Hospital, New York, NY, under a human institutional review board approved protocol. Samples were healthy tissues from surgical procedures performed on adults. Specimens were removed aseptically, rinsed in isotonic sodium chloride

5 solution to remove debris, and shipped at 4°C within 24 hours of procurement. Upon receipt of the tissue samples, upper respiratory tract epithelium from bronchus, nasal polyps, or turbinates was dissociated as described in Hicks et al., Abstract, "Rapid Isolation of Upper Respiratory Cells," Mol. Biol. Cell. 5(Suppl):118a (1994), which is hereby incorporated by reference.

Example 3 - Construction of Respiratory Epithelial Cell Containing Composite Cell Culture and Control Culture

10 After chondrocytes, cultured as described in Example 1, formed a layer of extracellular matrix, 0.5 mL of type I collagen (Vitrogen; Collagen Biomaterials, Palo Alto, CA) was added to wells, thereby forming the first two layers of the composite. After addition of the type I collagen, upper respiratory epithelial cells harvested according to Example 2 were added to type I collagen-coated chondrocytes
15 at $2 \times 10^5 / \text{cm}^2$, in DMEM/F-12, containing antibiotics, epidermal growth factor (10 ng/mL), hydrocortisone (1 $\mu\text{mol/L}$), insulin (5 $\mu\text{g/mL}$), L-isoproterenol (1 $\mu\text{mol/L}$), and 5% fetal calf serum. Cultures were aged for two weeks.

20 Upper respiratory epithelial cells harvested according to Example 2 were also added at the same density onto type I collagen-coated culture dishes (i.e., without a layer of chondrocytes in extracellular matrix), thereby forming control cultures. The control cultures were aged for two weeks like the composite cell cultures.

25 RECs grown on type I collagen formed a continuous sheet (Figures 3A-B). In contrast, RECs grown on composite cultures did not spread to confluence, but rather grew as discrete patches or plaques of epithelium (Figures 3C-D). The epithelial cell layer in both the composite cultures and on type I collagen was undifferentiated.

30 **Example 4 - Analysis of RECs and Chondrocytes for Growth Factor Expression**

RECs from the aged composite cell cultures and control cultures were removed from the cultures by microscopic dissection and processed for RT-PCR (reverse transcriptase polymerase chain reaction. RECs were also processed for

scanning electron microscopy (model 35CF; JEOL, Japan) at 10 to 12 kV. The cartilage supernatant was taken for zymogram analysis.

Chondrocyte cultures aged twenty-eight days were formalin fixed and processed for immunoperoxidase histochemical analysis. Rabbit polyclonal antibody to type II collagen (DAKO, Carpinteria, Calif) was applied, washed, and followed by a biotinylated universal secondary antibody and streptavidin peroxidase (Immunon/Shandon-Lipshaw, Pittsburgh, Pa).

In REC from day 14 composite cultures, expression of both TGF- α and TGF- β was reduced (Figure 4, lane 4, TGF- α ; lane 6, TGF- β) as compared with REC on type I collagen (Figure 4, lane 3, TGF- α ; lane 5, TGF- β). Relative expression of β -actin was equal (Figure 4, lanes 1 and 2). Paraffin sections of REC grown on type I collagen and on composites were immunostained for TGF- α and TGF- β . Both growth factors were expressed in chondrocytes, and to a lesser extent, in epithelial cells.

Total cellular RNA was isolated from day 14 REC composite cell cultures, and REC control cultures using TriReagent (Molecular Research Center, Cincinnati, Ohio) as described by the manufacturer. Under a dissecting microscope, the REC layer was removed from cultures with a sterile, RNase-free spatula into TriReagent. One to five micrograms of total RNA was reverse transcribed using murine Moloney leukemia virus reverse transcriptase (Kawasaki, PCR Protocols: A Guide to Methods and Applications, San Diego, CA, Academic Press (1990), which is hereby incorporated by reference). Polymerase chain reaction amplification was performed using primer sets for human TGF- α , TGF- β_1 , and β -actin (Clontech, Palo Alto, Calif), following manufacturer's instructions. One-tenth volumes of polymerase chain reaction products were run on 2.5% or 3% agarose gels and visualized by ethidium bromide staining. The polymerase chain reaction products obtained were of expected sizes (human β -actin, 838 base pairs; human TGF- β , 161 bp; and human TGF- α , 297 bp).

Both TGF- α and TGF- β play crucial roles in new tissue formation and remodeling. TGF- α stimulates proliferation in cultured epithelial cells (Derynck, "Transforming Growth Factor- α : Structure and Biological Activities," J. Cell Biochem. 32:293-304 (1986), which is hereby incorporated by reference), fibroblasts

(DeLarco et al., "Growth factors from murine sarcoma virus-transformed cells," Proc. Natl. Acad. Sci. USA 75:4001-4005 (1978), which is hereby incorporated by reference), and endothelial cells (Schreiber et al., "Transforming Growth Factor- α : A More Potent Angiogenic Mediator than Epidermal Growth Factor," Science 232: 1250-1253 (1986), which is hereby incorporated by reference). It is chemotactic for epithelial cells *in vitro* (Barrandon et al., "Cell Migration Is Essential for Sustained Growth of Keratinocyte Colonies: The Roles of Transforming Growth Factor- α and Epidermal Growth Factor," Cell 50:1131-1137 (1987), which is hereby incorporated by reference) and enhances epithelial wound healing when applied topically (Schultz et al., "Epithelial Wound Healing Enhanced by Transforming Growth Factor- α and Vaccinia Growth Factor," Science 235:350-352 (1987), which is hereby incorporated by reference). TGF- β is mitogenic for cells of mesenchymal origin and plays a role in repair through its ability to modulate extracellular matrix formation and tissue remodeling.

When isolated human RECs were cultured on type I collagen, the cells spread to form a confluent layer as has been previously reported by other authors (Robinson et al., "Culture of Conducting Airway Epithelial Cells in Serum-Free Medium," J. Tissue Cult. Method. 13:95-102 (1991), which is hereby incorporated by reference). When plated onto composite cultures with a layer of type I collagen on top of cartilage, the cells did not spread efficiently but formed epithelial nests. Complete reepithelialization of the surface did not occur, even after 3 weeks.

Due to the physical differences between REC layers on the composite cell cultures and control cultures, TGF- α and TGF- β expression was examined. Both of these growth factors were reduced in epithelial cells from 14-day composite cultures when compared with the expression of these factors in REC cultured on type I collagen alone. This suggests that the cartilage modulates the behavior of epithelial cells. Without being bound by theory, it is believed that the observed diminished expression of TGF- α and TGF- β results from the secretion of soluble factors from the cartilage. TGF- α was expressed in cartilage, where it may have acted on the epithelium in a paracrine manner to decrease its expression.

Example 5 - The Role of Matrix Metalloproteinases in Respiratory Epithelial Cell Attachment and Proliferation

Chondrocytes were harvested from bovine or porcine articular cartilage according to the procedure set forth in Example 1. Cell viability and number were determined by Trypan blue staining and counting using a hemocytometer.

Chondrocytes were plated on collagen inserts (Costar Transwell, VWR, Pittsburgh, PA) at $20\text{--}40 \times 10^6$ cells/well in DMEM/F12 containing antibiotics, 10% FBS, and 50 $\mu\text{g/ml}$ ascorbic acid (prepared fresh and added every other day). After the chondrocytes had formed a layer of extracellular matrix (approximately 2 weeks), the medium was switched to serum free (DMEM/F12 with antibiotics, 5 $\mu\text{g/ml}$ insulin, 15 $\mu\text{g/ml}$ bovine pituitary extract, 10 $\mu\text{g/ml}$ epidermal growth factor, 5 $\mu\text{g/ml}$ transferrin, 1 μM hydrocortisone, 10^{-8} M retinol, and ascorbic acid). Cultures were fed from the bottom every 3-4 days. Medium was collected from chondrocyte cultures on days 3, 5, 7, 10, and 14 after switching from 10% FBS-containing medium to SFM. The collected CCM was cleared by centrifugation to remove cell debris, pooled at every timepoint, and frozen at -20°C until assayed. No protease inhibitors were added to collected medium.

Porcine tracheal tissue obtained at necropsy was cleaned of debris, rinsed thoroughly with PBS, and epithelium and submucosa removed and soaked overnight at 4°C in MEM containing antibiotics/antimycotics. Dissociated respiratory epithelial cells were isolated using elastase digestion as described by Hicks et al. ("Rapid Isolation of Upper Respiratory Epithelial Cells," Mol. Biol. Cell., 5(Suppl.): 118a (Abstract), (1995); Hicks et al., "Isolation and Characterization of Basal Cells from Human Upper Respiratory Epithelium," Exp. Cell Res. 237:357-363 (1997), which are hereby incorporated by reference) and plated on top of type I collagen-coated 35 mm petri dishes at 0.2×10^6 cells/ cm^2 in serum free medium. In selected experiments, cells were cultured in Biocoat type I collagen-coated 24 well plates. Medium was collected for gelatin zymography as described above.

The proliferative effects of CCM on REC were assessed by addition of CCM diluted 1:1 with SFM. REC cultures grown on type I collagen were fed 0.1 ml CCM or control SFM daily, and media were changed completely every 3 days. At selected timepoints (days 5, 7, 10, and 14), cell cultures were harvested for

determination of cell number by counting using a hemocytometer. For cells cultured on type I collagen 35 mm petri dishes, medium was removed and dishes rinsed twice with PBS. Type II collagenase at 2 mg/ml in PBS was added and the cultures incubated at 37°C with gentle shaking for 45-60 minutes to allow digestion of the collagen substrate. Cells were collected and 10% FBS in DMEM added to stop digestion. Cells were washed once with PBS, and 2X trypsin/EDTA solution added to further dissociate cells from the matrix and from one another. After incubation at 37°C for 20 minutes, REC were again washed with PBS/10% FBS, then resuspended in PBS and an aliquot counted using Trypan blue dye exclusion to determine viability and cell number. For cells cultured in Biocoat 24 well plates, cells were removed by trypsinization, washed once in PBS/FBS and re-suspended in PBS for counting as described above. Results were similar between the two culture methods.

In selected experiments, GM6001, a broad-spectrum matrix metalloproteinase inhibitor, or its negative control peptide (both available from Calbiochem, San Diego, CA), were added to cells cultured in the presence or absence of CCM.

Seven and a half percent acrylamide gels were cast with 1 mg/ml gelatin as substrate. Latent proteases in media or standards were activated by incubating samples with 1 mM aminophenylmercuric acetate for 1 hour at 37°C prior to electrophoresis.

CCM or SFM, obtained as described above, was mixed with 2X sample buffer (20 mM DTT, 4% SDS, 50 mM Tris, 20% glycine, 0.002% Bromophenol blue), loaded without prior heating, and electrophoresed under non-reducing conditions at 4°C for approximately 4 hours under constant voltage. MMP-2 and MMP-9 standards (available from Chemicon, Temecula, CA) and kaleidoscope prestained molecular weight standards (available from Biorad, Hercules, CA) were included in every gel. After electrophoresis, gels were removed and washed twice in 2.5% Triton X-100 for 15 minutes each, then incubated in developing buffer (50 mM Tris-HCl, 0.2 M NaCl, 10 mM CaCl₂, 0.02% (w/v) Brij 35, pH 7.5) overnight at 37°C, with moderate shaking. Some gels were incubated in developing buffer containing 20 mM EDTA (ethylenediamine tetraacetic acid) to chelate Zn² and inactivate the MMPs. Gels were rinsed twice with distilled water then stained for 1 hour in

Coomassie blue stain, followed by destaining in water/methanol/acetic acid (6: 3.5: 0.5) until clear areas of enzyme activity were detected against a blue background. Estimates of amounts of MMPs present in CCM were made by comparison of known concentrations of MMP standards with dilutions of CCM and scanning the clear areas of substrate lysis on the gel by laser densitometry.

Experiments were performed a minimum of twice on independent tracheal REC preparations. Data were analyzed by ANOVA or t-test, as appropriate, with a level of statistical significance at $P < 0.05$.

CCM from days 3, 5, 7, 10, and 14 was subjected to gelatin zymography on 7.5% SDS-PAGE gels. Several major bands of gelatinolytic activity were detected (Figure 5A). Three distinct bands were observed at 105-125 kDa and two bands were detected at approximately 92 and 88 kDa. A major broad band was detected at 72 kDa with minor bands visible at 65-68 kDa. Based on comparisons with purified MMP-2 and -9 standards run in parallel with the samples, the areas of enzyme activity at 92 and 88 kDa corresponded to proMMP-9 and to active MMP-9. The bands of activity at 72 kDa corresponded to proMMP-2, and the lower molecular weight forms to activated forms of MMP-2. The higher molecular forms may represent additional gelatinases. When zymograms were developed in the presence of the chelator EDTA, enzyme activity was abolished and the clear areas of lysis disappeared, confirming the enzyme activity as belonging to matrix metalloproteinases (Figure 5B).

Coincident with the secretion of matrix metalloproteinase-2 (MMP2, 72 kDa gelatinase) in cartilage, as determined by gel zymography, RECs that previously strongly expressed TGF- α and TGF- β had a decrease in the expression of both of these proteins in the composite cell culture.

SFM did not contain MMP activity (Figure 5A, lane 3). Medium conditioned by respiratory epithelial cells cultured in SFM contained barely detectable MMP activity (Figure 5A, lane 4). Conditioned medium from chondrocytes grown for 3 days in either 10% serum-containing medium or for 3 days after the switch to SFM exhibited considerable MMP activity as revealed by gelatin zymography (Figure 5A, lanes 5 and 6, respectively).

If matrix metalloproteinases were being secreted from chondrocytes, this may be a contributing factor in failure of epithelial cells to proliferate and spread to confluence over the covering type I collagen layer in the composite co-culture system (described in Example 3, *supra*). To ascertain this, serum-free CCM from days 3-14 was pooled and diluted in 1:1 with serum-free medium. This medium was fed to respiratory epithelial cells plated on type I collagen, and cell number was determined on day 7 of culture. Cell number was reduced by 61.3% in cultures that received CCM compared with controls that received SFM alone (Figure 6), suggesting that MMPs secreted by chondrocytes may interfere with epithelial cell proliferation.

In order to investigate whether MMPs were directly responsible for diminished REC proliferation, an inhibitor of matrix metalloproteinases (GM6001) or its control peptide were added to REC cultured with or without CCM and cell number was determined after 7 days in culture. Addition of GM6001 or its control peptide at a concentration of 5 nM (10 fold higher than the K_i) did not block marker protein activity in pooled CCM as determined by gelatin zymography (Figures 7A-B), nor was proliferation positively affected by addition of the inhibitor. In a second series of experiments, GM6001 or control peptide were used at concentrations of 10 and 50 W, but once again proliferation was not restored to control levels (Figure 8).

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.

WHAT IS CLAIMED:

1. An *in vitro* cell culture device comprising:
a vessel comprising an inner surface;
a layer of cartilage disposed on at least a portion of said inner surface,
said layer of cartilage comprising a plurality of chondrocytes in an extracellular matrix; and
a growth medium in said vessel, said layer of cartilage being bathed in said growth medium.
2. The *in vitro* cell culture device according to claim 1, wherein said vessel is formed of glass or plastic.
3. The *in vitro* cell culture device according to claim 2, wherein said vessel is in the form of a petri dish.
4. The *in vitro* cell culture device according to claim 1, wherein said extracellular matrix comprises type II collagen.
5. The *in vitro* cell culture device according to claim 4, wherein said type II collagen is a substantial portion of said extracellular matrix.
6. The *in vitro* cell culture device according to claim 1, wherein said chondrocytes are upper airway cartilage chondrocytes.
7. The *in vitro* cell culture device according to claim 1, further comprising:
a second layer comprising type I collagen, said second layer being disposed on said layer of cartilage.
8. The *in vitro* cell culture device according to claim 7, wherein said type I collagen is a substantial portion of said second layer.

9. A composite cell culture comprising:
a first layer comprising chondrocytes in an extracellular matrix;
a second layer, disposed on the first layer, comprising type I collagen; and
a third layer, disposed on the second layer, comprising cells at least partially covering the second layer.

10. The composite cell culture according to claim 9, wherein the cells are epithelial cells, fibroblasts, endothelial cells, epidermal cells, muscle cells, or combinations thereof.

11. The composite cell culture according to claim 10, wherein the cells are epithelial cells.

12. The composite cell culture according to claim 11, wherein the epithelial cells are upper respiratory epithelial cells.

13. The composite cell culture according to claim 11, wherein the epithelial cells are present as a plurality of distinct plaques dispersed throughout the third layer.

14. The composite cell culture according to claim 13, wherein the extracellular matrix is type II collagen.

15. The composite cell culture according to claim 9, wherein the chondrocytes are articular or upper airway cartilage chondrocytes.

16. The composite cell culture according to claim 15, wherein the cells are upper respiratory epithelial cells.

17. The composite cell culture according to claim 16, wherein the upper respiratory epithelial cells are present as a plurality of distinct plaques dispersed throughout the third layer.

18. The composite cell culture according to claim 15, wherein the extracellular matrix is type II collagen.

19. The composite cell culture according to claim 15, wherein chondrocytes are upper airway cartilage chondrocytes.

20. A method for preparing an *in vitro* composite cell culture comprising:
providing an *in vitro* cartilage layer comprising chondrocytes in an extracellular matrix;
disposing a type I collagen layer on the cartilage layer; and
contacting the type I collagen layer with cells under conditions effective for the cells to multiply and at least partially cover the layer of type I collagen.

21. The method according to claim 20, wherein said providing an *in vitro* cartilage layer comprises:
providing a chondrocyte single cell suspension; and
culturing the chondrocytes under conditions effective to form an extracellular matrix, thereby forming cartilage *in vitro*.

22. The method according to claim 21, wherein said providing a chondrocyte single cell suspension comprises:
providing articular cartilage comprising chondrocytes embedded in an extracellular matrix; and
treating the articular cartilage with collagenase II under conditions effective to digest the extracellular matrix and produce a chondrocyte single cell suspension.

23. The method according to claim 21, further comprising:
providing a type I collagen substrate.

24. The method according to claim 23, wherein said culturing comprises:
introducing the chondrocyte single cell suspension onto the type I collagen substrate at a cell density of about $1-10 \times 10^6$ cells/cm².

25. The method according to claim 20, the cells are respiratory epithelial cells.

26. A method of screening putative therapeutic agents for activity in promoting re-epithelialization of cartilaginous tissues comprising:

introducing a putative therapeutic agent into a composite cell culture according to claim 12 and

assessing epithelial cell growth on the composite cell culture, wherein increased surface area coverage of the plurality of distinct plaques indicates that the putative therapeutic agent has activity in promoting re-epithelialization of cartilaginous tissues.

27. A method of screening putative therapeutic agents for activity in promoting re-epithelialization of cartilaginous tissues comprising:

providing an *in vitro* cell culture device according to claim 1;

introducing a layer of type I collagen onto the layer of cartilage;

introducing epithelial cells onto the layer of type I collagen, thereby forming a composite cell culture;

introducing a putative therapeutic agent into the composite cell culture;
and

assessing epithelial cell growth on the composite cell culture, wherein growth and migration of epithelial cells beyond distinct plaques thereof indicates that the putative therapeutic agent has activity in promoting re-epithelialization of cartilaginous tissues.

28. The method according to claim 27, wherein said introducing epithelial cells and said introducing the putative therapeutic agent are carried out simultaneously.

29. The method according to claim 27, wherein said introducing epithelial cells is carried out after said introducing the putative therapeutic agent.

30. A method of screening putative therapeutic agents for activity in inhibiting a growth factor or proteinase which prevents re-epithelialization of cartilaginous tissues comprising:

introducing a putative therapeutic agent into a composite cell culture according to claim 12 and

assessing epithelial cell growth on the composite cell culture, wherein increased surface area coverage of the plurality of distinct plaques indicates that the putative therapeutic agent has activity in inhibiting a growth factor or proteinase which prevents re-epithelialization.

31. A method of screening putative therapeutic agents for activity in inhibiting a growth factor or proteinase which prevents re-epithelialization of cartilaginous tissues comprising:

providing an *in vitro* cell culture device according to claim 1;

introducing a layer of type I collagen onto the layer of cartilage;

introducing epithelial cells onto the layer of type I collagen, thereby forming a composite cell culture;

introducing a putative therapeutic agent into the composite cell culture;

and

assessing epithelial cell growth on the composite cell culture, wherein growth and migration of epithelial cells beyond distinct plaques thereof indicates that the putative therapeutic agent has activity in inhibiting a growth factor or proteinase which prevents re-epithelialization.

32. The method according to claim 31, wherein said introducing epithelial cells and said introducing the putative therapeutic agent are carried out simultaneously.

33. The method according to claim 31, wherein said introducing epithelial cells is carried out after said introducing the putative therapeutic agent.





Fig. 1



Figs. 2A-C






Fig. 4



Figs. 3A-D



Figs. 5A-B






Fig. 6



Figs. 7A-B




Fig. 8

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US00/14526

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/00, 5/02; C12M 3/00

US CL : 435/325, 391, 395, 402, 288.1, 305.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/325, 391, 395, 402, 288.1, 305.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,326,357 A (KANDEL) 05 July 1994, see entire document, especially col. 5, line 1 - col. 8, line 33.	1, 2, 4, 5
X	US 5,786,217 A (TUBO et al) 28 July 1998, see entire document, especially col. 4, line 3 - col. 7, line 27, and col. 10, line 24 - col. 11, line 11.	1, 2, 4-6
X	US 4,846,835 A (GRANDE) 11 July 1989, see entire document, especially col. 7, line 19 - col. 8, line 6.	1, 2, 4, 5
Y	US 5,607,920 A (KATO et al) 04 March 1997, col. 2, lines 49-57.	1-3



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search


15 AUGUST 2000

Date of mailing of the international search report

04 October 2000

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

 Authorized officer

 CHRISTOPHER TATE

Telephone No. (703) 308-0196